ABSTRACT Aims Computational pathology platforms incorporate digital microscopy with sophisticated image analysis to permit rapid, continuous measurement of protein expression. We compared two computational pathology platforms on their measurement of breast tumour oestrogen receptor (ER) and progesterone receptor (PR) expression. Methods Breast tumour microarrays from the Nurses' Health Study were stained for ER (n=592) and PR (n=187). One expert pathologist scored cases as positive if ≥1% of tumour nuclei exhibited stain. ER and PR were then measured with the Definiens Tissue Studio (automated) and Aperio Digital Pathology (usersupervised) platforms. Platform-specific measurements were compared using boxplots, scatter plots and correlation statistics. Classification of ER and PR positivity by platform-specific measurements was evaluated with areas under receiver operating characteristic curves (AUC) from univariable logistic regression models, using expert pathologist classification as the standard. Results Both platforms showed considerable overlap in continuous measurements of ER and PR between positive and negative groups classified by expert pathologist. Platform-specific measurements were strongly and positively correlated with one another (r≥0.77). The usersupervised Aperio workflow performed slightly better than the automated Definiens workflow at classifying ER positivity (AUC Aperio =0.97; AUC Definiens =0.90; difference=0.07, 95% CI 0.05 to 0.09) and PR positivity (AUC Aperio =0.94; AUC Definiens =0.87; difference=0.07, 95% CI 0.03 to 0.12). Conclusions Paired hormone receptor expression measurements from two different computational pathology platforms agreed well with one another. The user-supervised workflow yielded better classification accuracy than the automated workflow. Appropriately validated computational pathology algorithms enrich molecular epidemiology studies with continuous protein expression data and may accelerate tumour biomarker discovery.
INTRODUCTION
Cancer epidemiologists increasingly rely on highthroughput measurement of host and tumour molecular characteristics in large study populations. Expression of proteins in breast tumour tissue is an essential facet of molecular characterisation for both clinical and research purposes. 1 2 For example, immunohistochemical (IHC) staining of breast tumours for oestrogen receptor (ER) identifies patients who will benefit from adjuvant anti-oestrogen therapy. 3 Assessment of ER in combination with progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), cytokeratin 5/6 and epidermal growth factor receptor permits epidemiologists to explore how risk factor associations differ for breast cancer molecular subtypes. 4 Unfortunately, characterisation of tumour protein expression largely relies on manual interpretation by trained pathologists, at the cost of significant time expenditure and inevitable interreader variability. Furthermore, workloads are often multiplied by the necessity of evaluating several protein targets at once. Pathologist evaluation of tumour protein expression has therefore become a rate-limiting step in modern molecular epidemiology studies. A potential solution to this problem is the adoption of computational pathology systems that incorporate digital microscopy with quantitative image analysis software. 5 We compared the performance of two such systems in measuring breast tumour expression of ER and PR on continuous scales, with readings by a single expert pathologist.
MATERIALS AND METHODS Study population
We compared performance of the Aperio and Definiens computational pathology systems by measuring expression of ER and PR in formalinfixed, paraffin-embedded tumour tissues from breast cancer cases in the Nurses' Health Study (NHS) cohort. The NHS is thoroughly described elsewhere. 6 Since 1993 tumour tissue has been requested from pathology departments at treating hospitals for NHS breast cancer cases without a history of another malignancy (except nonmelanoma skin cancer). Of the 10 988 cases eligible for collection, tumour blocks and pathology data have been obtained for 6591. For each breast cancer case, three 0.6 mm tumour cores were placed into one of 38 tissue microarrays (TMAs) for IHC assays. Many more of these cases have been evaluated with the Definiens system than with the Aperio system. For the present study, five of the breast tumour TMAs (n=592 cases, representing the intersection between cases evaluated with Definiens and cases evaluated with Aperio) were evaluated for ER expression; three of these five TMAs (n=187) were also evaluated for PR expression.
IHC for hormone receptors and expert pathologist review
IHC assays for ER and PR were performed on 5 μm sections cut from the breast cancer TMAs. Before staining, paraffin was removed by serial xylene treatment followed by rehydration in graded alcohol/water solutions. Endogenous peroxidases were blocked by incubating tissues with 1% hydrogen peroxide in methanol for 10 min. Antigens were retrieved by incubating tissues in citrate buffer ( pH 6.0) for 30 min at high heat. ER was detected with a monoclonal antibody (Dako Cytomation clone #1D5, Carpinteria, California, USA) at a 1:200 dilution factor with a 1-hour incubation at room temperature. PR was detected with a monoclonal antibody (Dako Cytomation clone #PgR636, Carpinteria, California, USA) at a 1:50 dilution factor with a 30 min incubation at room temperature. After washing away unbound primary antibody, tissues were incubated for 1 hour with a biotinylated horse-anti-mouse secondary antibody (Vector Labs, Burlingame, California, USA) at a 1:250 dilution factor, followed by 1-hour incubation with Vectastain Elite ABC streptavidin-horseradish peroxidase conjugate (Vector Labs, Burlingame, California, USA) at a 1:200 dilution factor. Bound complexes were visualised with diaminobenzidine following signal potentiation (0.5% copper sulfate in normal saline for 5 min). All slides were counterstained with haematoxylin. All TMAs were stained for ER or PR in single runs on a Dako Autostainer (Dako, Carpinteria, California, USA). All TMAs were manually reviewed and scored by a single expert breast pathologist (LCC) at the Beth Israel Deaconess Medical Center (BIDMC) before any data were collected from the computational pathology systems.
Automated image analysis
Using expert breast pathologist classification as benchmarks, we compared the performance of two computational pathology systems on their continuous measurement of ER and PR positivity in breast tumours. The first system, Aperio Digital Pathology (Leica Biosystems, Buffalo Grove, Illinois, USA), integrates a digital microscope with image analysis software. In our implementation of the Aperio system, pathologists were required to review each tumour core image, manually outline regions of invasive tumour, flag regions to ignore (eg, chromogen deposits, nonspecific staining and folded-over tissue) and specify an appropriate image analysis algorithm. The second system, Definiens Tissue Studio (Definiens AG, Munich, Germany), is a software suite which requires input of a raw TMA image from a thirdparty digital slide scanner. In our implementation of the Definiens system, we used the software to automatically identify regions of tumour tissue and did not require manual review of each tissue core. As a result, our implementation of the Definiens system represented a workflow option with minimal user input that can spare time and personnel expense. ER and PR measurements on the Aperio platform used the built-in "nuclear v9" algorithm. ER and PR measurements on the Definiens platform used the built-in Definiens Tissue Studio algorithm for quantification of protein expression from nuclear stains (complete parameters are available from the corresponding author).
Definitions of analytic variables
Expert pathologist classification of ER expression was recorded both dichotomously (negative vs ≥1% of tumour nuclei positive) and categorically (negative, 1%-9% of tumour nuclei positive or ≥10% of tumour nuclei positive). Expert pathologist classification of PR expression was only classified dichotomously (negative vs ≥1% of tumour nuclei positive). Both the Aperio and Definiens systems scored nuclear staining intensity on a 4-level ordinal scale, with 0 denoting no stain and 3 denoting the strongest staining. Among the wealth of data generated for each tissue core by the Definiens and Aperio algorithms are the total number of tumour nuclei evaluated and the number of tumour cores exhibiting each staining level. These measurements were summarised for each tumour core using two quantities namely, the positivity index and the histological score. The positivity index is equal to the proportion of tumour nuclei with any positive staining (range: 0-100) and gives equal weight to all staining intensities. In contrast, the histological score (h) weights the proportion of positive nuclei by their staining intensity (range: 0-300). In the equation below, p i denotes the proportion of tumour nuclei exhibiting staining at different intensity levels (i=0 for no staining, i=1 for low staining, i=2 for moderate staining and i=3 for strong staining). For the breast cancer cases-each of which was represented by up to three tumour cores-ER and PR positivity indices and histological scores were summarised as the mean across evaluated cores.
We collected descriptive data on demographic factors and tumour characteristics for the breast cancer cases using biennial NHS questionnaires and the pathology reports from treating hospitals. Age was defined at the time of breast cancer diagnosis. Year of diagnosis was categorised into six periods: 1990-1991, 1992-1993, 1994-1995, 1996-1997, 1998-1999 and 2000-2002 . Tumour size was categorised as 0.1-1.0 cm, 1.1-2.0 cm and ≥2.1 cm. Tumour histology and grade were based on evaluation of TMAs by BIDMC breast pathologists. Histology was classified as invasive ductal carcinoma, invasive lobular carcinoma, both invasive ductal and lobular carcinoma, in situ disease or other histological type. Grade was classified as well differentiated, moderately differentiated or poorly differentiated.
Statistical analysis
We tabulated the frequency and proportion of breast cancer cases measured for ER and PR on the Definiens and Aperio platforms according to demographic and tumour characteristics. For cases represented by three tumour cores with a non-zero mean measurement, we calculated the coefficient of variation (CV; the SD divided by the mean) of the measurement across cores. We characterised the location and dispersion of continuous ER and PR measurements with summary statistics and boxplots within joint strata of computational pathology platform and dichotomous expert pathologist classification. Mean measurements across platforms were compared with Wilcoxon signed-rank tests. To compare case-by-case agreement on continuous ER and PR measurements, we plotted platform-specific values of cases' positivity indices or histological scores against one another and calculated Pearson's correlation coefficients. For ER we evaluated correlations between the platformspecific continuous measurements and the ordinal expert pathologist classification (negative, 1%-9% of tumour nuclei positive and ≥10% of tumour nuclei positive) using Spearman's correlation coefficients without correction for de-attenuation. 7 We compared correlation coefficients between platforms by calculating differences and accompanying 95% CIs.
We compared the platforms' ER and PR classification accuracies using dichotomous expert pathologist classifications as standards. Using pathologist ER and PR calls as regressands, we fit multivariable logistic models with paired Aperio and Definiens measurements (mean positivity index or mean histological score) as independent variables. From these models we calculated the area under receiver operating characteristic (ROC) curves (AUC), estimated from platform-specific measures. Using the ROC curves we determined classification statistics (sensitivity and specificity) for positivity index or histological score cut-points of 5, 10 and 20. We also calculated classification statistics for the optimal cut-points, which we defined as those yielding the maximum sum of sensitivity and specificity. Classification performance was compared by calculating differences in platform-specific AUCs and accompanying 95% CIs.
All analyses were performed with SAS (V.9.4; SAS Institute, Cary, North Carolina, USA); statistical tests were two-sided with a type I error rate of 5%. Table 1 shows tumour and demographic characteristics for the evaluated cases. There were 592 and 187 breast cancer cases evaluated for ER and PR expressions, respectively, by both the Definiens and Aperio systems. The distribution of evaluable core count was similar between the two systems. Overall, about two-thirds of the breast cancer cases were represented by three evaluable tumour cores. Among these cases, the median CV for continuous ER and PR measurements ranged between 23.1% and 33.3%, with maximum values ranging from 114% to 173%. The distribution of CV values was similar for both platforms and for both positivity index and histological score (see online supplementary tables S1 and S2). The proportion of cases represented by only a single tumour core ranged from 7% (for ER measured by Definiens) to 15% (for PR measured by Definiens). Year of diagnosis ranged between 1990 and 2002 for cases with ER measurements and between 1990 and 1997 for cases with PR measurements. ER and PR subsets were similar with respect to the distribution of patient age, tumour size and histological types. Invasive cancer cases with PR measurements were less likely to have poorly differentiated tumours compared with invasive cases with ER measurements.
RESULTS
The distribution of continuous ER and PR measurements are depicted graphically for the positivity index in figure 1 and are depicted graphically for the histological score in online supplementary figure S1. Corresponding summary statistics are reported in online supplementary tables S1 and S2. Among cases classified as ER-negative by an expert pathologist (n=116 (20%)), the mean positivity index was similar for both platforms, but it was measured with less precision by Definiens (Definiens: mean±SD=11.4±14.3, range=0.1-84.8; Aperio: mean±SD=10.3±7.9, range=0-38.5; p for difference=0.21); a similar pattern was evident for histological score. Among cases classified as ER-positive by an expert pathologist (n=476 (80%)), the mean positivity index on the Definiens platform was lower than the mean positivity index on the Aperio platform (Definiens: mean±SD=42.1±24.8, range=0.9-99.1; Aperio: mean±SD=54.7±26.0, range=4.9-99.6; p for difference <0.0001); a similar pattern was evident for the histological score. Regardless of platform, there was considerable overlap in the ranges of ER measurements between the positive and negative categories of expert pathologist classification. In both the PR-negative stratum (n=62 (33%)) and the PR-positive stratum (n=125 (67%)), mean positivity index and mean histological score were higher on the Definiens platform than on the Aperio platform. As seen with ER, there was considerable overlap in the ranges of PR measurements between strata of PR status by expert pathologist.
The boxplots in the upper-left panel of figure 1 -which represent the distribution of mean ER positivity index among cases classified as negative by expert pathologist-show several high outlier observations on both platforms. These outlier observations are from seven individual breast cancer cases. Only one of these cases was an outlier on both platforms. Of the remaining six outliers, five were unique to Definiens and only one was unique to Aperio. Visual analysis of tumour cores from these cases showed that cores from the single outlier on both platforms and all five of the outliers unique to the Definiens system had regions of folded or sloughing tissue in addition to chromogen deposits that were misinterpreted as positive nuclei. The single statistical outlier unique to the Aperio system appeared to be truly ER-positive and its positivity index measurements from Aperio and Definiens were quite similar (38.53 and 34.20, respectively). Figure 2 shows scatter plots of Definiens mean positivity index against corresponding Aperio measures for both ER and PR (scatter plots based on histological score are shown in online supplementary figure S2 ). Marker shapes encode each case's While the Definiens histological score also showed a tendency towards higher values than the Aperio histological score among cases deemed negative by pathologists, the magnitude was much less pronounced than for the positivity index. Table 2 reports Spearman correlations between platformspecific ER positivity index or histological score and the expert pathologists' ordinal classification of ER expression (negative, 1%-9% of tumour nuclei positive or ≥10% of tumour nuclei positive). Within platforms, correlation coefficients were similar (or identical) for the positivity index and the histological score. Both measurements from the Aperio system were more strongly correlated with the three-level ER variable than corresponding measurements from the Definiens system (eg, Aperio positivity index Spearman's r=0.66; Definiens positivity index Spearman's r=0.54; difference=0.12, 95% CI 0.08 to 0.16). Table 3 compares Definiens and Aperio measurements on their potential to correctly classify cases as ER-positive or PR-positive, using dichotomous expert pathologist classifications (negative vs ≥1% tumour nuclei positive) as standards. Both positivity index and histological score showed excellent ER and PR classification potentials, reflected by AUCs ranging from 0.83 to 0.97. The AUCs for histological score were consistently (though modestly) higher than AUCs for positivity index within ER/PR and Definiens/Aperio groups (eg, for PR measurements on the Definiens platform, positivity index AUC=0.83, 95% CI 0.76 to 0.89; histological score AUC=0.87, 95% CI 0.81 to 0.92). AUCs for Aperio measurements were consistently higher than AUCs for Definiens measurements (eg, for ER positivity index, Aperio AUC=0.96, 95% CI 0.95 to 0.98; Definiens AUC=0.88, 95% CI 0.84 to 0.91). Differences between Aperio and Definiens AUC values ranged from 0.07 to 0.10 (table 3) .
Online supplementary table S3 shows classification parameters for different ER-positive cut-points of the positivity index and histological score. We defined optimal cut-points as those that yielded the greatest sum of sensitivity and specificity. For the Definiens platform, the optimal positivity index cut-point was ≥21% (sensitivity=74.8%, false-positive rate (FPR)=12.9%) and the optimal histological score cut-point was ≥27 (sensitivity=75.5%, FPR=10.3%). For the Aperio platform, the optimal positivity index cut-point was ≥25% (sensitivity=84.1%, FPR=4.3%) and the optimal histological score cut-point was ≥25 (sensitivity=88.7%, FPR=6.9%). Corresponding cut-points and classification parameters for progesterone receptor are reported in Supplemental Table 4 .
DISCUSSION
We compared two commercially available computational pathology platforms on their measurement of continuous hormone receptor expression in archival breast tumour TMAs from the NHS cohort-an ideal example of the type of research setting which stands to benefit from adoption of computational pathology systems. The two platforms were implemented with different workflows. Our Aperio implementation required a considerably greater amount of effort per case evaluated but was expected to yield a lower false-positive classification rate for the marker of interest in return. And while the Definiens system can be operated with a similar degree of user scrutiny and input, we chose to implement a largely automated process to increase time efficiency, although at the potential expense of higher false-positive classification rates.
We found considerable overlap in values of both positivity index and histological score (regardless of platform) between strata of pathologist-determined ER status and PR status (figure 1 and see online supplementary figure S1). Pathologists used a cut-off of ≥1% of tumour nuclei staining positive to classify dichotomous ER status and PR status. Nonetheless, there were cases deemed ER-negative by pathologists with positivity index values as high as 84.8 on the Definiens system and 38.5 on the Aperio system (see online supplementary table S1) and there were cases deemed PR-negative by pathologists with positivity index values as high as 78.0 on the Definiens system and 21.9 on the Aperio system (see online supplementary table S2). This lack Table 2 Correlations between continuous measurements with three-level pathologist-determined oestrogen receptor status of congruence may be partially explained by low-intensity nuclear staining that is interpreted as positive by the computational pathology algorithms but is correctly recognised as nonspecific staining by expert pathologists. It follows from this that the highest values of the Aperio system's ER and PR positivity index ranges are substantially lower than the highest values of the Definiens system's ER and PR positivity index ranges, since regions of non-specific staining would have been flagged for exclusion during the manual review process for Aperio. Definiens and Aperio measurements correlated strongly with one another. However, scatter plots showed further evidence of the Definiens positivity index being overly sensitive among cases deemed ER-negative or PR-negative by expert pathologists (figure 2), with a substantial number of observations exhibiting much higher readings than those returned by the Aperio. This was much less evident for the Definiens histological score, which weights positive nuclei according to their staining intensity and is therefore able to de-emphasise (but not completely discount) potential false-positive, lightly stained nuclei.
Compared with Definiens, measurements from the Aperio system yielded stronger correlations with ordinal ER status (table 2) and better classification accuracy with respect to goldstandard dichotomous ER and PR statuses (table 3) . However, the modest gains in correlation and classification accuracy were not in proportion to the considerably greater amount of time required by our Aperio implementation to prepare scanned tumour cores for image analysis. Both Aperio and Definiens allow users to customise image analysis parameters and the Definiens system can be operated with as much user specification of analysis regions as the Aperio system. Together, these steps allow for fine-tuning the platforms' output to match specific research objectives. The continuous measurements provided by the systems promise to expand future research endeavours, such as modelling cancer risk heterogeneity and predicting responses to adjuvant therapy according to increasing levels of clinically important biomarkers. The continuous data could also be used to define cut-points for dichotomous classifiers that minimise the proportion of false-negative or false-positive cases.
Other studies have evaluated performance of computational pathology systems for the measurement of breast tumour biomarkers. One group showed 100% concordance between semiquantitative pathologist readings for ER (n=10 cases) and HER2 (n=23 cases) and corresponding semi-quantitative readings from both Definiens and Aperio using whole-slide tumour images. 8 Another group used a custom-built, fully automated nuclear algorithm to measure ER and PR expressions in 743 primary breast tumours. 9 Validation against pathologist readings was done for only 18 cases, but it showed a strong, positive correlation (Spearman's r=0.9, p<0.001); the authors used the continuous ER and PR data to define optimal cut-points for predicting survival and response to tamoxifen treatment. 9 To our knowledge, our study is the largest-yet comparison of computational pathology measurements with expert pathologist measurement of ER and PR in breast tumours.
It should be noted that the cases in our analysis were not a random sample of all breast cancer cases in the NHS cohort and that ER and PR measurements were made for minor subsets of the 6,494 NHS breast cancer cases for which tumour tissues have been collected and placed in TMAs. The sizes of the ER and PR subsets were limited by the number of cases evaluated on the Aperio platform, which in turn was limited by that platform's slower workflow. While such a highly selected sample might generate bias in an epidemiological study of breast cancer risk factors, our objective was simply to make comparisons of measurements on common sets of tumour tissue from breast cancer cases. As such, our analytic samples were appropriate for achieving our aims.
Information bias is another potential limitation. We used manual classification of ER and PR statuses by an expert pathologist as gold standards for comparing platforms, even though they are subject to measurement error. One potential bias scenario under such measurement error is that cases could be falsely classified negative by pathologists while yielding positive signal in image analysis algorithms. This could partly explain the high range of positivity index values among ER-negative and PR-negative cases described above. It is impossible to speculate about the existence and magnitude of this bias in the absence of a better standard. However, our assessment of statistical outliers among cases deemed ER-negative by an expert pathologist showed only one instance where an apparently positive tumour core was deemed negative by the pathologist.
In summary, the highly automated implementation of the Definiens platform performed marginally poorer than the highly supervised implementation of the Aperio platform in classifying breast tumour ER and PR statuses in TMAs. With careful optimisation and validation, automated computational pathology platforms may prove quite useful for molecular epidemiology studies in which finer classification of protein expression beyond typical ordinal or dichotomous schemes is desired or necessary.
Take home messages
▸ Computational pathology platforms may be used to enrich molecular epidemiology studies with continuous protein expression data. ▸ An algorithm with extensive user supervision performed better at classifying breast tumour hormone receptor status than a more time-efficient fully automated algorithm. ▸ With careful development and validation, automated computational pathology algorithms may equip molecular epidemiology studies with data for finer definition of tumour molecular subtypes in a time-efficient and cost-efficient manner.
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